The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...
Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...
DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...
Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...
Over the past decade, the rising cost of insulin epitomized the broader systemic issue of higher healthcare out-of-pocket ...
Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...
Living with Type 1 diabetes is a numbers game. There’s not a moment in the day free from the burden of tracking your blood ...
New research suggests that wearing continuous glucose monitors could lower the risk of dementia. Experts discuss how symptoms can overlap between diabetes and dementia.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback